Cantor Fitzgerald lowered the firm’s price target on Rapt Therapeutics to $40 from $44 and keeps an Overweight rating on the shares following the Q4 results. The readout timeline for the Phase 2B trial of RPT193 in atopic dermatitis is delayed to mid-2024 from the firm’s prior expectation of 4Q23 due to slower-than-expected patient enrollment driven by seasonality, the analyst tells investors in a research note. Rapt is looking at steps to speed up enrollment, the firm says, adding that the delay is not driven by any concerns related the drug and would be a buyer here.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RAPT:
- Rapt Therapeutics Craters as Testing Proves a Challenge
- RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
- Rapt Therapeutics reports Q4 EPS (64c), consensus (66c)
- Rapt Therapeutics says $2M of cash held at Silicon Valley Bank
- RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference